CD274 and neoplasm: This can explain why patients with high tumor PD-L1 expression may not benefit from checkpoint inhibitor therapy, or patients who exhibit lower levels of PD-L1 expression may demonstrate a more favorable response than initially anticipated, considering IHC [13], thus making it evident that a better diagnostic tool is needed to select for PD-L1 therapy.